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1 Introduction
Phototherapy has proven to be a very potent tool
for the prevention as well as for the therapy of
different forms of hyperbilirubinemia. This does
not exclude different approaches to the problem,
for instance the induction of bilirubin eliminating
processes by drugs. This approach might be par-
ticularly promising in newborns, who suffer from
additional disturbances such as hypoxia, infection,
acidosis or hemolytic disease and extreme imma-
turity, which may facilitate the development of a
bilirubin encephalopathy.
In 1968 TROLLE [20] introduced phenobarbital
(PB) into the prevention of hyperbilirubinemia in
newborns. Because of its marked sedative effect
in dosages, which are necessary to reduce the
plasma bilirubin concentration sufficiently, respi-
ratory depression is frequently seen in infants, who
are especially prone to develop bilirubin enceph-
alopathy, such as very immature newborns or
those with prior cerebral damage. Thus a combi-
nation with nikethamid, an analeptic with a good
inductive effect, has been recommended [6, 7].
However, this combination was not with out dan-
gerous side effects in those infants, who need a
prophylactic treatment of hyperbilirubinemia.
Methylphenobarbital (MPB), an antiepileptic drug
introduced by BLUM 1932 [1], is still in use for
adults including pregnant women [14] as well as
for infants. Because of its chemical configuration
it is a racement of two optically active isomeres.
The (+)isomer has no sedative effect [3, 4, 5]. The
inductive activity acting on different metabolic
systems in animals, however, is common for both
isomers [8, 9, 13, 18, 21], and comparable to the
activity of phenobarbital. MPB proved to be a
potent inductor in man as well [5, 11]. Up to now
there are no investigations on its inductive activity
in newborns. From our own data, until now un-
published, as well as from investigations of HILL
and coworkers [10], one may conclude that MPB
is well absorbed from the gut after oral adminis-
tration and that the half life of MPB, which is
metabolized to PB and at least five minor metab-
olites [11], is less than 30 hours. SCHMID and BAL-
LOWITZ [17] were able to show that MPB does not
influence the bilirubin binding to albumin — this
goes for both the racemete and the (H-)isomer.
These results encouraged us, to investigate the
effect of MPB-racemate on the bilirubin concen-
tration of mature newborn babies in a double-
blind trial.
2 Patients, design and methods of the study
198 newborn babies weighing more than 2500 g
received MPB racemate or a placebo. MPB was
mixed with glucose to form a powder. The single
doses — MPB with glucose or glucose alone —
were enclosed in paperenvelopes. Different brands
of the verum were prepared containing 30 mg of
MPB for babies weighing 2500 g to 3499 g or 40
mg for those weighing 3500 g to 4499 g in order
to administer single doses of about 10 mg/kg body
weight.
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Envelopes with identical contents were combined
into one set. The sets were prepared and blinded
by a pharmacist, who kept the key locked up until
the end of the study. Each baby was assigned to
one set and received the first poweder between the
8th and 12th hour of life, the two others 8 and 16
hours later. Bilirubin was estimated from venous
blood before the first administration and between
48 and 72 and 72 and 96 hours of life respectively.
We used the method of JENDRASSIK and GROF [12]
for the bilirubin analysis. Because of organiza-
tional problems most of the babies were dis-
charged shortly after the 96th hour of life. There-
fore the bilirubin level could be followed only up
to four days after birth. Informed consent was
obtained from each mother. For statistical analysis
we used the u-test.
3 Results
Table I shows some basic data of the groups, which
could be suspected to influence the bilirubin level.
It is shown that there was no significant difference
in gestational age, sex-ratio, birth weight and
weight loss, body length and immediate postnatal
adaptation. All babies passed meconium during
the first 24 hours. In no baby did the bilirubin
level exceed 230 μηιοΐ/ΐ. Therefore no photother-
apy was necessary. No other problems like such
as, poor sucking, breathing difficulties or somno-
lence were observed.
Table II shows the results of the bilirubin concen-
tration. Already on day three there is a slight
however statistically not significant difference be-
tween the bilirubin concentration in the plasma of
the two groups. One day later there is a decreased
plasma bilirubin concentration in the study group
on MPB, whereas the bilirubin concentration still
increased in the babies on placebo. The difference
between the bilirubin levels of the two groups on
day four is statistically significant (p < 0,001).
There is an insignificant difference, if one looks
upon the two subgroups with different birth
weights. The effect seems to be a little bit more
pronounced in the infants with lower birth weight
(figure 1).





























body length (cm) 50.5 ± 1.74 50.5 ± 1.58
Table Π: Comparison of plasma bilirubin concentration (μιηοΙ/1) (mean + SD)
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Δ 3 500g - 4 499g
Figure 1: Plasma bilirubin-concentration in fullterm neonates of different birthweight after administration of 3 χ 10
mg/kg MPB or placebo on the first day of life.
4 Discussion
Different drugs are in development and research
for the prevention and therapy of neonatal hyper-
bilirubinemia, i.e. clofibrate [15, 16], flumezinol
[2]. The unique properties of the (H-)isomer of
MPB, which is an excellent inductor of different
enzymes and lacks the sedative effect of PB might
make it well suited for the prevention and early
therapy of neonatal hyperbilirubinemia. Up to
now the (+)isomer of MPB was not available in
sufficient amounts for clinical trials. Therefore we
used the racemate for our preliminary investiga-
tion. The effect in mature newborns after early
treatment is comparable to the results of GMYREK
and coworkers [6] with PB and PB in combination
with nikethamid. The difference in the plasma
bilirubin concentration on day four in their series
was 29,5 μηιοΐ/ΐ between the group treated by
verum and that on placebo. This difference
amounted to about 25% of the concentration in
the control babies. The differences found in our
investigation on day four amounts to 29.1 μηιοί/
1, i.e. 33% of the concentration in the control
infants. Similar results were also obtained by
STERN and coworkers [19] as early as 1970 using
PB. On day four they had found nearly identical
differences between the treated and the control
group: 1.98 mg/100 ml (= 33.7 μηιοΐ/ΐ) corre-
sponding to 29% of the concentration in the con-
trol infants.
We suppose that the effect in premature babies,
who might be in greater need for pharmacological
treatment of hyperbilirubinemia than mature new-
borns would show analogous effects. The slight
difference between the birth weight groups (figure
1) may be a weak suggestion that the effect of
MPB is more pronounced in infants with lower
gestational age. The difference in gestational age
between the two groups, however, amounts to no
more than 0.5 weeks with a slightly higher SD of
1.6 weeks.
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The results of our study do not justify a recom-
mendation of MPB for the treatment or preven-
tion of neonatal hyperbilirubinemia, however, they
promise interesting and useful results, if the inves-
tigations are carried out in premature babies using
the (H-)isomer alone. Performing some pharma-
cokinetic studies would be necessary as well.
Abstract
In order to find a drug for the prevention of metabolic
hyperbilirubinemia of the newborn, which has less sed-
ative effects than phenobarbital (PB) the effect of meth-
ylphenobarbital (MPB) on the plasma bilirubin concen-
tration of newborns was studied in a double blind trial.
MPB (3x10 mg/kg on the first day) reduced the plasma
bilirubin level in mature newborns on day four by 33%
in comparison to those on placebo. The results justify
further investigations in premature babies, who fre-
quently suffer from disturbances which may facilitate
the development of bilirubin encephalopathy.
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Zusammenfassung
Induktion Bilirubin eliminierender Prozesse durch Me-
thylphenobarbital (MPB) bei reifen Neugeborenen
Die medikamentöse Induktion Bilirubin eliminierender
Prozesse ist trotz der bewährten Fototherapie zur Pro-
phylaxe des Neugeborenenikterus bei Neugeborenen in
Erwägung zu ziehen, die durch zusätzliche Anpassungs-
störungen, Hypoxie, Azidose, Hämolyse, Infektionen
oder extreme Unreife besonders zur Entwicklung einer
Bilirubinenzephalopathie neigen.
Methylphenobarbital (MPB), das als Antieleptikum im
Gebrauch ist, ist ein Razemat zweier aktiver Isomere,
deren (+)-Isomer keine sedative Wirkung hat. Demge-
genüber haben beide Isomere in unterschiedlichen Sy-
stemen an Mensch und Tier eine dem PB vergleichbare
Aktivität als Induktoren Bilirubin eliminierender Pro-
zesse. MPB ist bisher am Neugeborenen nicht unter-
sucht.
Wir untersuchten in einem Doppelblindversuch die Wir-
kung des MPB-Razemats auf den Plasma-Bilirubinspie-
gel reifer Neugeborener. 198 Neugeborene mit Geburts-
gewichten von mehr als 2500 g erhielten dreimal in den
ersten 24 Lebensstunden je 10 mg/kg MPB-Razemat.
Der Bilirubinspiegel im Venenblut wurde vor der ersten
Verabreichung, am dritten und vierten Lebenstag unter-
sucht. Am vierten Lebenstag fiel die Bilirubinkonzentra-
tion im Plasma der MPB-Gruppe bereits wieder ab,
während sie in der Plazebo-Gruppe noch anstieg. Der
Konzentrationsunterschied am vierten Lebenstag zwi-
schen den beiden Gruppen war statistisch signifikant
(p < 0,001).
Die Eigenschaften des ( + )-Isomers von MPB lassen es
für den Einsatz in der Prophylaxe der Neugeborenen-
hyperbilirubinämie sehr geeignet erscheinen: es ist ein
hervorragender Induktor verschiedener Enzyme und hat
keinen sedativen Effekt. Derzeit ist das (+)-Isomer in
hinreichenden Mengen für einen klinischen Versuch
nicht verfügbar. Wir benutzten für unsere orientierenden
Untersuchungen daher das Razemat. Seine Wirksamkeit
ist der des PB und des PB in Kombination mit Niketha-
mid, wie sie von GMYREK u. a. verwendet wurden, voll
vergleichbar.
Weitere Untersuchungen an Frühgeborenen unter Ver-
wendung des (H-)-Isomers scheinen vielversprechend.
Schlüsselwörter: Bilirubinelimination, Enzyminduktion, Methylphenobarbital, Neugeborenenikterus.
Resume
Induction de processes d'elimination de la bilirubine par
le methylphenobarbital chez les nouveaux-nes matures
L'induction medicamenteuse des processus d'elimination
de la bilirubine pourrait etre une approche prometteuse
de la prevention de l'ictere des nouveaux-nes qui
souffrent de troubles associes tels que l'hypoxie, l'infec-
tion, l'acidose ou la maladie hemolytique et Pimmaturite
majeure, tous elements qui facilitent l'apparition d'en-
cephalopathie a la bilirubine.
Le Methylphenobarbital (MPB), medicament frequem-
ment utilise comme antiepileptique et un racemique de
deux isomeres optiquement actifs. L'isomere (+) n'a pas
d'effet sedatif. L'activite d'induction de differents sys-
temes metaboliques chez Pannimal et chez rhomme est
neanmoins specifique des deux isomeres et eile est
comparable ä l'activite du Phenobarbital. Nous avons
etudie par une etude en double aveugle l'effet du MPB
racemique sur la concentration plasmatique du biliru-
bine chez des nouveaux nes matures.
198 enfants pesant plus de 2500 g ont recu du MPB
racemique (3 10 mg/Kg au cours du premier jour de
vie) ou un placebo. La bilirubine a ete dosee dans le
J. Perinat. Med. 16 (1988)
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sang veineux avant la premiere administration et entre
respectivement 48 heures et 72 heures de vie et 72 et 96
heures.
Au quatrieme jour il y a une diminution de la bilirubine
plasmatique dans le groupe etudie, alors que dans le
groupe placebo les concentrations de bilirubine conti-
nuent d'augmenter (tableau II). La difference entre les
taux de bilirubine des deux groupes au quatrieme jour
est significative (p < 0,001).
L'effet est comparable aux resultats de GMYREK et coll
avec le PB et le PB assoce au nikethamide (coramine).
Les resultats de notre etude justifient Fetude chez les
prematures de Fisomere (+) seul.
Mots-cles: Elimination de la bilirubine, ictere du nouveau-ne, induction enzymatique, Methylphenobarbital.
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